Golden
Distributed Bio

Distributed Bio

A company developing antibody discovery, engineering, informatics tools and services for the life sciences research and drug discovery markets. 

All edits

Edits a day ago
Aleksander Holm
Aleksander Holm edited a day ago
Edits made to:
Article (+76/-52 characters)

Article

TheyThrough werethe profitablelicensing of their software platform, they built cash early on, and was able to build an antibody discovery and optimization lab. From there Distributed Bio was able to license the data and the ability to engineer new medicines.

...

AbGenesis was initially built in 2012 and was Distributed Bio's original technology. The AbGenesis repertoire analysis and engineering environment enableenables analyses of individual cells to millions of B-cell and T-cell receptors, this includes linking of sequence and phenotype data. Users can interrogatesearch sequence data, identify candidate clones, analyze CDR diversity, analyze library selections, analyze hybridoma and immunizationa data, and monitor immune responses. 

Edits 2 days ago
Carla Faraguna
Carla Faraguna edited 2 days ago
Edits made to:
Timeline (+12/-118 characters)

Timeline

October 25, 2018

Charles River Laboratories, Inc. (NYSE: CRL) today announcedannounces that it has entered into an exclusive partnership with Distributed Bio, Inc., a leader in the computational design and optimization of antibody discovery platformsInc.

Carla Faraguna
Carla Faraguna edited 2 days ago
Edits made to:
Article (+9/-8 characters)

Article

Using Distributed Bio's epitope focusing technology, their vaccine, Centivax, is able to focus a subjectssubject's immune response against parts of pathogens unable to mutate and induce antibodies. Using pre-2009 viral strain information, Centivax was able to neutralize immunity against future pandemic and seasonal viral strains. This is primarily focused on influenza in the animal and human markets, but provides potential for other markets.

Edits 5 days ago
Aleksander Holm
Aleksander Holm edited 5 days ago
Edits made to:
Infobox (+17/--1 properties)
Timeline (+2 events) (+438 characters)
Article (+2689/-465 characters)
People (+22 rows) (+64 cells) (+1644 characters)
Documentaries, videos and podcasts (+1 rows) (+3 cells) (+55 characters)

Article

A Johnson & Johnson JLABS resident, Distributed Bio analyzed thousands of human immune systems with its machine learning platform called AbGenesis to have produced the SuperHuman library with 76 billion antibodies, including over 5,000 hits against each of the 26 targets in immuno-oncology and neurodegeneration within Distributed Bio's pipeline.

Distributed Bio was founded by Jacob Glanville, Giles Day and Chris Smith in 2012. They didn't seek traditional venture capital, but instead built a software platform on Amazon Cloud which allowed people globally to do computational immunology. 

...

Pfizer and Boehringer Ingelheim have both licensed Distributed Bio's human monoclonal antibody library SuperHuman 2.0.

They were profitable early on, and was able to build an antibody discovery and optimization lab. From there Distributed Bio was able to license the data and the ability to engineer new medicines.

Technologies

AbGenesis

AbGenesis was initially built in 2012 and was Distributed Bio's original technology. The AbGenesis repertoire analysis and engineering environment enable analyses of individual cells to millions of B-cell and T-cell receptors, this includes linking of sequence and phenotype data. Users can interrogate sequence data, identify candidate clones, analyze CDR diversity, analyze library selections, analyze hybridoma and immunizationa data, and monitor immune responses. 

SuperHuman-2.0

A Johnson & Johnson JLABS resident, Distributed Bio analyzed thousands of human immune systems with its machine learning platform called AbGenesis to have produced the SuperHuman library with 76 billion antibodies, including over 5,000 hits against each of the 26 targets in immuno-oncology and neurodegeneration within Distributed Bio's pipeline.

...

Pfizer and Boehringer Ingelheim have both licensed Distributed Bio's human monoclonal antibody library SuperHuman 2.0. Charles River partnered with Strategic bio to create an end-to-end platform for therapeutic antibody discovery and development.

...

The SuperHuman library allows for cross-species coverage, developability profiles for thermostability, aggregation potential and immunogenicity. In October of 2019, Distributed Bio announced the release of SuperHuman 3.0, which is a Single Light Chain (SLiC) library. 

Tungsten

Distributed Bio's Tungsten 1.0 is a computationally optimized synthetic single domain library based on camelid repertoire. The library includes a camelid framework for reagent development and a human VH3-23 framework for therapeutic development.

Centivax

Using Distributed Bio's epitope focusing technology, their vaccine, Centivax, is able to focus a subjects immune response against parts of pathogens unable to mutate and induce antibodies. Using pre-2009 viral strain information, Centivax was able to neutralize immunity against future pandemic and seasonal viral strains. This is primarily focused on influenza in the animal and human markets, but provides potential for other markets.

Tumbler

Tumbler is Distributed Bio's antibody engineering technology which uses artificial intelligence to generate antibodies in greater quantity and shorter time than traditional methods.

People

Name
Role
LinkedIn

Aishani Aatresh

Computational Immunology



Austin Sanchez

Lab Coordinator



Chelsea Jones

Associate Scientist

Chris Smith

Founder and Chief Technology Officer

Christina Pettus, PSM

Scientist

David Gangemi

Director of Virology



David Maurer, PSM

Director of Internal Engineering

Devin Pineda

Protein Engineering

Giles Day, MSc

Founder and Chief Operations Officer

Jacob Glanville, PhD

Founder, Chief Executive Officer and President

Jessica Salas

Associate Scientist

Lilja Klempan

Executive Administrator

Lindsay Blore

Project Manager

Mary Mathieu

Senior Scientist

Raymond Newland, PSM

Scientist

Sarah Ives, PSM

Director of Contract Research

Sawsan Youssef, PhD

Chief Science Officer

Shahrad Daraeikia

Associate Scientist

Sindy Liao

Principal Scientist

Timothy Yung

Software Engineer

Valerie Chiou, PSM

Scientist

Documentaries, videos and podcasts

Title
Date
Link

Distributed Bio

June 9, 2018

Infobox

Timeline

October 11, 2019

Distributed Bio Inc and Good Therapeutics, Inc. Announce Multi-Target Collaboration 

October 25, 2018

Charles River and Distributed Bio Enter Exclusive Partnership to Create an Integrated Antibody Discovery and Development Platform

Charles River Laboratories, Inc. (NYSE: CRL) today announced that it has entered into an exclusive partnership with Distributed Bio, Inc., a leader in the computational design and optimization of antibody discovery platforms.

Edits on 7 Mar 2019
Golden AI
Golden AI edited on 7 Mar 2019 10:05 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 5 Mar 2019
Carla Faraguna
Carla Faraguna approved a suggestion from Golden's AI on 5 Mar 2019 2:48 am
Edits made to:
Infobox (+2 properties)
Edits on 1 Oct 2018
Carla Faraguna
Carla Faraguna edited on 1 Oct 2018 5:39 pm
Edits made to:
Article (+19/-19 characters)

Article

A Johnson & Johnson Johnson & Johnson JLABS resident, Distributed Bio analyzed thousands of human immune systems with its machine learning platform called AbGenesis to have produced the SuperHuman library with 76 billion antibodies, including over 5,000 hits against each of the 26 targets in immuno-oncology and neurodegeneration within Distributed Bio's pipeline.

...

Pfizer and Boehringer Ingelheim have both licensed Distributed Bio's human monoclonal antibody library SuperHuman 2.0.

Edits on 29 Sep 2018
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 29 Sep 2018 8:45 pm
Edits made to:
Article (+20/-20 characters)

Article

Pfizer and Boehringer IngelheimBoehringer Ingelheim have both licensed Distributed Bio's human monoclonal antibody library SuperHuman 2.0.

Edits on 28 Sep 2018
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 28 Sep 2018 11:04 pm
Edits made to:
Article (+6/-6 characters)

Article

PfizerPfizer and Boehringer Ingelheim have both licensed Distributed Bio's human monoclonal antibody library SuperHuman 2.0.

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 28 Sep 2018 11:04 pm
Edits made to:
Article (+19/-19 characters)

Article

Pfizer and Boehringer Ingelheim have both licensed Distributed Bio's human monoclonal antibodymonoclonal antibody library SuperHuman 2.0.

Carla Faraguna
Carla Faraguna edited on 28 Sep 2018 5:40 pm
Edits made to:
Infobox (+1 properties)
Description (+144 characters)
Article (+687 characters)
Categories (+1 topics)
Related Topics (+3 topics)
Topic thumbnail

Distributed Bio

A company developing antibody discovery, engineering, informatics tools and services for the life sciences research and drug discovery markets. 

Article

An immuno-engineering company providing computational tools and antibody libraries. It has computational platform for analysis and engineering of antibodies, TCRs and peptides and discovery platform of antibody libraries.



A Johnson & Johnson JLABS resident, Distributed Bio analyzed thousands of human immune systems with its machine learning platform called AbGenesis to have produced the SuperHuman library with 76 billion antibodies, including over 5,000 hits against each of the 26 targets in immuno-oncology and neurodegeneration within Distributed Bio's pipeline.



Pfizer and Boehringer Ingelheim have both licensed Distributed Bio's human monoclonal antibody library SuperHuman 2.0.



Infobox

Categories

Related Topics

Edits on 14 Jun 2018
Golden AI"Initial topic creation"
Golden AI created this topic on 14 Jun 2018 5:24 pm
Edits made to:
Topic thumbnail

 Distributed Bio

A company developing antibody discovery, engineering, informatics tools and services for the life sciences research and drug discovery markets. 

No more activity to show.